Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

[1]  J. Fashner,et al.  Common gastrointestinal symptoms: irritable bowel syndrome. , 2013, FP essentials.

[2]  J. Fichna,et al.  Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases. , 2013, Current drug targets.

[3]  M. Storr,et al.  The cannabinoid‐1 receptor inverse agonist taranabant reduces abdominal pain and increases intestinal transit in mice , 2013, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[4]  J. Anastasi,et al.  Managing Irritable Bowel Syndrome , 2013, The American journal of nursing.

[5]  R. Su,et al.  Effect of thienorphine on intestinal transit and isolated guinea-pig ileum contraction. , 2013, World journal of gastroenterology.

[6]  J. Fichna,et al.  Characterization of the effects of opiorphin and sialorphin and their analogs substituted in position 1 with pyroglutamic acid on motility in the mouse ileum , 2013, Journal of peptide science : an official publication of the European Peptide Society.

[7]  M. Ko,et al.  The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. , 2013, ACS chemical neuroscience.

[8]  J. Fichna,et al.  Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives , 2013, Journal of Gastroenterology.

[9]  A. Dahan,et al.  Non-analgesic effects of opioids: opioid-induced respiratory depression. , 2012, Current pharmaceutical design.

[10]  J. Fichna,et al.  Brain-Gut Interactions in IBS , 2012, Front. Pharmacol..

[11]  S. Husbands,et al.  Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. , 2011, Journal of medicinal chemistry.

[12]  W. MacNaughton,et al.  Differential effects of salvinorin A on endotoxin‐induced hypermotility and neurogenic ion transport in mouse ileum , 2011, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[13]  Albert Dahan,et al.  Current Knowledge of Buprenorphine and Its Unique Pharmacological Profile , 2010, Pain practice : the official journal of World Institute of Pain.

[14]  J. Fichna,et al.  Synthesis and biological evaluation of novel peripherally active morphiceptin analogs , 2010, Peptides.

[15]  Y. Taché,et al.  Repeated psychological stress-induced alterations of visceral sensitivity and colonic motor functions in mice: Influence of surgery and postoperative single housing on visceromotor responses , 2010, Stress.

[16]  P. Schiller.  Bi- or multifunctional opioid peptide drugs. , 2010, Life sciences.

[17]  A. Janecka,et al.  Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating κ‐opioid and cannabinoid receptors , 2009, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[18]  N. Zaveri,et al.  Comparison of the Antinociceptive and Antirewarding Profiles of Novel Bifunctional Nociceptin Receptor/μ-Opioid Receptor Ligands: Implications for Therapeutic Applications , 2009, Journal of Pharmacology and Experimental Therapeutics.

[19]  N. Zaveri,et al.  Nociceptin/Orphanin FQ Receptor Activation Attenuates Antinociception Induced by Mixed Nociceptin/Orphanin FQ/μ-Opioid Receptor Agonists , 2009, Journal of Pharmacology and Experimental Therapeutics.

[20]  S. Salvadori,et al.  Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. , 2009, British journal of anaesthesia.

[21]  G. Calo’,et al.  Activities of mixed NOP and μ‐opioid receptor ligands , 2008, British journal of pharmacology.

[22]  G. Holtmann,et al.  Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: spinal cord c-Fos expression and behavior. , 2007, American journal of physiology. Gastrointestinal and liver physiology.

[23]  Z. Gong,et al.  Thienorphine Is a Potent Long-Acting Partial Opioid Agonist: A Comparative Study with Buprenorphine , 2006, Journal of Pharmacology and Experimental Therapeutics.

[24]  Richard Payne,et al.  Buprenorphine: considerations for pain management. , 2005, Journal of pain and symptom management.

[25]  K. Schiene,et al.  Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. , 2005, European journal of pharmacology.

[26]  F Ivy Carroll,et al.  Buprenorphine-Induced Antinociception Is Mediated by μ-Opioid Receptors and Compromised by Concomitant Activation of Opioid Receptor-Like Receptors , 2003, The Journal of Neuroscience.

[27]  E. García-Nicas,et al.  A new model of visceral pain and referred hyperalgesia in the mouse , 2001, PAIN®.

[28]  A. Cowan,et al.  THE ANIMAL PHARMACOLOGY OF BUPRENORPHINE, AN ORIPAVINE ANALGESIC AGENT , 1977, British journal of pharmacology.

[29]  A. Cowan,et al.  AGONIST AND ANTAGONIST PROPERTIES OF BUPRENORPHINE, A NEW ANTINOCICEPTIVE AGENT , 1977, British journal of pharmacology.